ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2025

Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians.

John R P Tesser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.